Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
111.79
+1.28 (1.16%)
At close: Sep 30, 2026, 4:00 PM EDT
111.79
0.00 (0.00%)
After-hours: Sep 30, 2026, 4:15 PM EDT
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $65.00M in the quarter ending June 30, 2026, with 466.40% growth. This brings the company's revenue in the last twelve months to $105.00M, up 134.84% year-over-year. In the year 2025, Kymera Therapeutics had annual revenue of $39.21M, down -16.70%.
Revenue (ttm)
$105.00M
Revenue Growth
+134.84%
P/S Ratio
90.82
Revenue / Employee
$384,615
Employees
273
Market Cap
9.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 39.21M | -7.86M | -16.70% |
| Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
| Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
| Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
| Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
| Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
| Dec 31, 2019 | 2.93M | - | - |
| Dec 31, 2018 | 2.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 989.61M |
| TG Therapeutics | 799.54M |
| Axsome Therapeutics | 776.57M |
| Arrowhead Pharmaceuticals | 669.50M |
| Krystal Biotech | 440.48M |
| Protagonist Therapeutics | 281.99M |
| ImmunityBio | 165.79M |
| Cytokinetics | 67.67M |
KYMR News
- 2 days ago - Kymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan - TheFly
- 6 days ago - Kymera Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 6 days ago - Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs - TheFly
- 8 days ago - Kymera Therapeutics price target raised to $152 from $132 at Stifel - TheFly
- 14 days ago - Kymera Therapeutics management to meet with Piper Sandler - TheFly
- 15 days ago - Kymera Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 16 days ago - Kymera Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 16 days ago - Kymera Therapeutics price target raised to $144 from $123 at BofA - TheFly